Results 231 to 240 of about 5,697,314 (319)

Implementation of clinical decision support tools for treatment selection in knee osteoarthritis: a scoping review. [PDF]

Ther Adv Musculoskelet Dis
Cochrane JA, Roberts O, Ribbons K, Clark R, Pua YH, Tan TL, Thwin L, Leung YY, Liow MHL, Tan BY, Nilsson M.   +10 more
europepmc   +1 more source

PARP inhibition and pharmacological ascorbate demonstrate synergy in castration‐resistant prostate cancer

Molecular Oncology, EarlyView.
Pharmacologic ascorbate (vitamin C) increases ROS, disrupts cellular metabolism, and induces DNA damage in CRPC cells. These effects sensitize tumors to PARP inhibition, producing synergistic growth suppression with olaparib in vitro and significantly delayed tumor progression in vivo. Pyruvate rescue confirms ROS‐dependent activity.
Nicolas Gordon, Peter T. Gallagher, Orly I. Richter, Neermala Poudel Neupane, Amy C. Mandigo, Jennifer J. McCann, Emanuela Dylgjeri, Irina Vasilevskaya, Christopher McNair, Channing J. Paller, Wm. Kevin Kelly, Karen E. Knudsen, Matthew J. Schiewer, Ayesha A. Shafi   +13 more
wiley   +1 more source

Editorial: Neurocomputational models of decision-making and cognitive processes

Frontiers in Human Neuroscience
Lidia Ghosh, Anuradha Saha
doaj   +1 more source

Primate-informed neural network for visual decision-making. [PDF]

Proc Natl Acad Sci U S A
Su J, Cai F, Zhao SK, Wang XY, Qian TY, Wang DH, Hong B.   +6 more
europepmc   +1 more source

LDAcoop: Integrating non‐linear population dynamics into the analysis of clonogenic growth in vitro

Molecular Oncology, EarlyView.
Limiting dilution assays (LDAs) quantify clonogenic growth by seeding serial dilutions of cells and scoring wells for colony formation. The fraction of negative wells is plotted against cells seeded and analyzed using the non‐linear modeling of LDAcoop.
Nikko Brix, Daniel Samaga, Katharina Gehr, Benedek Dankó, Mohamed Schumann, Guido Drexler, Ahmed Alnatsha, Georg Beyer, Ujjwal Mahajan, Martin Selmansberger, Julia Mayerle, Claus Belka, Horst Zitzelsberger, Kirsten Lauber   +13 more
wiley   +1 more source

Optimising Transport Decision Making using Customised Decision Models and Decision Conferences [PDF]

, 2012
Barfod, Michael Bruhn
core  

Plecstatin inhibits hepatocellular carcinoma tumorigenesis and invasion through cytolinker plectin

Molecular Oncology, EarlyView.
The ruthenium‐based metallodrug plecstatin exerts its anticancer effect in hepatocellular carcinoma (HCC) primarily through selective targeting of plectin. By disrupting plectin‐mediated cytoskeletal organization, plecstatin inhibits anchorage‐dependent growth, cell polarization, and tumor cell dissemination.
Zuzana Outla, Jan Kosla, Magdalena Prechova, Lukas Frick, Patricia Bortel, Yasmin Borutzki, Andrea Bileck, Christopher Gerner, Samuel M. Meier‐Menches, Selma Osmanagic‐Myers, Martin Gregor   +10 more
wiley   +1 more source

Healthcare Decision-Making Ecosystem Deengineering. [PDF]

Cureus
Papalexandris S, Fotiadis T, Seremeti L, Folinas D, Anastasiadou SD.   +4 more
europepmc   +1 more source

Therapeutic strategies for MMAE‐resistant bladder cancer through DPP4 inhibition

Molecular Oncology, EarlyView.
We established monomethyl auristatin E (MMAE)‐resistant bladder cancer (BC) cell lines by exposure to progressively increasing concentrations of MMAE in vitro. RNA sequencing showed DPP4 expression was increased in MMAE‐resistant BC cells. Both si‐DPP4 and the DPP4 inhibitor sitagliptin suppressed the viability of MMAE‐resistant BC cells.
Gang Li, Shuichi Tatarano, Hirofumi Yoshino, Saeki Saito, Mitsuhiko Tominaga, Junya Arima, Ikumi Fukuda, Takashi Sakaguchi, Ryosuke Matsushita, Yasutoshi Yamada, Hideki Enokida   +10 more
wiley   +1 more source

Core Competencies of the Modern Geriatric Cardiologist: A Framework for Comprehensive Cardiovascular Care in Older Adults. [PDF]

J Clin Med
Esser R, Mondragon A, Larbaneix M, Esteban M, Farges C, Nisse Durgeat S, Maurou O, Harboun M.   +7 more
europepmc   +1 more source